FDA Panel To Find If Regeneron Gout Drug's Risks Too High
A U.S. Food and Drug Administration advisory panel should consider whether the apparent effectiveness of a Regeneron Pharmaceuticals Inc. gout treatment outweighs the increased risk of cancer it may bring, agency...To view the full article, register now.
Already a subscriber? Click here to view full article